GI Effects® Microbial Ecology Profile

A Targeted Stool Test for Optimal Clinical Utility

Proceed to Clinical Overview

The GI Effects® Microbial Ecology Profile is a targeted stool test evaluating gut microbiome balance and assessing bacteria and parasites. Combining the best mix of molecular and culture technology, this stool test provides:

  • More Actionable Results using Top Technologies and Premier Biomarkers

    • PCR (Polymerase Chain Reaction), a molecular assay optimized for stool testing assesses 24 commensal bacteria associated in the scientific literature with health and disease, and provides valuable insight into the human microbiome.

    • O&P (ova & parasite), the gold standard for parasite identification

      • Choice of either 1 or 3 day collection, based on clinician index of suspicion for parasitic infection.
      • If low/no suspicion, a one day sample will likely be adequate. If high suspicion, a 3-day sample collection is optimal

    • Enhanced Test Reporting that includes an Interpretation At-a-Glance overview that highlights clinically actionable biomarkers in three key areas of gut health: Infection, Inflammation, and Imbalance (Metabolic).

  • Broad Clinical Applications

    • Gastrointestinal function is critical for good health. Emerging evidence in the scientific literature has associated gut microbiome status with a wide variety of common illnesses including, but not limited to:

      • Irritable Bowel Syndrome (IBS)
      • Inflammatory Bowel Disease (IBD)
      • Diabetes
      • Obesity
      • Cardiovascular Disease
      • Celiac and Other Malabsorption Disorders
      • Mood Disorders
      • Autoimmune
      • Autism


Clinical Overview

What is the GI Effects Microbial Ecology Profile?

Primarily focusing on the “G” in the DIG format, our GI Effects Microbial Ecology Profile is a targeted stool test, offering the ability to detect and identify parasites, as well as providing valuable assessment of gut microbiota via 24 Commensal Bacteria targets.

Gut Microbiome:

  • Commensal bacteria — the composition, diversity, and relative abundance of gut organisms, all of which are linked to both gastrointestinal and general health
    • More than 95% of commensal gut organisms are anaerobic and are difficult to recover by traditional (aerobic) culture techniques; molecular DNA techniques are now considered the standard for anaerobic bacteria assessment in research, permitting identification and quantification of multiple organisms with a single specimen.
    • The Polymerase Chain Reaction (PCR) methodology can identify bacterial populations at any level of taxonomy, as broadly as phylum and as narrowly as species. This ability permits analysis of the gut microbiome at a desired degree of complexity.
    • GI Effects assesses a key set of 24 clinically relevant genera/species that map to 7 major phyla

  • Bacterial and mycological culture — the presence of specific beneficial and pathological organisms
    • Traditional bacterial culture complements DNA-based tests to provide an expanded survey of a patient's gut microbiota, beyond the specific organisms targeted by PCR.

  • Parasitology
    • GI Effects provides microscopic examination of fecal specimens for ova and parasites (O&P), the gold standard of diagnosis for many parasites.
    • Enzyme immunoassay (EIA), widely recognized for its diagnostic utility in the detection of pathogenic antigens, is used for the identification of Cryptosporidium, Entamoeba histolytica, and Giardia lamblia.

  • Additional biomarkers available:
    • Campylobacter EIA
    • Clostridium difficile EIA
    • Escherichia coli EIA
    • Helicobacter pylori Stool Antigen EIA
    • Fecal Lactoferrin (Inflammation/Immunology)

When should the GI Effects Microbial Ecology Profile be considered?

The GI Effects® Microbial Ecology Profile is a focused clinical tool in the management of patients with symptoms related to pathogenic organism and/or microbial imbalance. Such imbalances have been associated in the scientific literature with a wide variety of common illnesses including, but not limited to:

  • Irritable Bowel Syndrome (IBS)
  • Inflammatory Bowel Disease (IBD)
  • Diabetes
  • Obesity
  • Cardiovascular Disease
  • Celiac and Other Malabsorption Disorders
  • Mood Disorders
  • Autoimmune
  • Autism

The GI Effects Microbial Ecology Profile is particularly helpful in monitoring changes to microbiota as targeted therapeutics are implemented.

What advantage does Microbial Ecology Profile Stool testing offer compared to other diagnostics?

GI Effects Microbial Ecology Profile represents the best technical platform available to assess the status of the gut ecosystem, combining an optimized PCR molecular assay for anaerobic bacteria, Matrix Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) technology for identification of cultivable species, and gold standard O&P (ova & parasites) for parasite detection.

The test report is organized so that the clinician may move through results in a logical order that enhances clinical utility, starting with an innovative Interpretation At-a-Glance cover page.

  • Using evidence-based rules and weighted algorithms, this page synthesizes patient test results into Three Functional Pillars of clinical significance (Infection-Inflammation-Imbalance) and provides a directional indication of potential therapeutic next steps in patient management.
  • Diversity Association and Relative Abundance of gut microbiota is also reported on this page, providing both a proxy measure of gut biodiversity and the patient's levels of selected key organisms relative to similar measures in a healthy cohort of individuals

What can clinicians and patients expect from GI Effects Microbial Ecology Profile stool testing?

The results of the GI Effects Microbial Ecology Profile may effectively provide insight into the root cause(s) of gut symptoms originating from a disturbed gut ecosystem. Results can help to guide focused treatments designed to get patients back to good health. As identified functional imbalances in the gut microbiome become more normalized through targeted dietary, lifestyle, and supplementation therapeutics, intractable symptoms often improve for many patients.

Each biomarker is associated with specific pertinent therapies, but general therapeutic considerations include:

  • Discerning general evidence of bowel inflammation and providing intestinal mucosal and anti-inflammatory support
  • Addressing any identified infection with appropriate pharmacological and botanical treatments
  • Supporting commensal bacteria with pre/probiotic supplements and dietary changes

A targeted diagnostic panel, like the GI Effects Microbial Ecology Profile, is particularly helpful in monitoring changes to microbiota as individualized therapeutics are implemented. It also provides enhanced clinical accuracy in determining which patients may need more comprehensive stool testing.

Test Type: Stool Test

Analyte List
Akkermansia muciniphila
Anaerotruncus colihominis
Bacteriology
Bacteroides vulgatus
Bacteroides-Prevotella group
Barnesiella spp.
Bifidobacterium longum
Bifidobacterium spp.
Butyrivibrio crossotus
Clostridium spp.
Collinsella aerofaciens
Color
Consistency
Coprococcus eutactus
Desulfovibrio piger
Escherichia coli
Faecalibacterium prausnitzii
Fecal Occult Blood
Firmicutes/Bacteroidetes (F/B Ratio)
Fusobacterium spp.
Lactobacillus spp.
Methanobrevibacter smithii
Mic Sensitivities, Yeast or Bacteria
Microscopic Exam Results
Mycology (Yeast/Fungi)
Odoribacter spp.
Other Biomarkers
Oxalobacter formigenes
Parasitology
Parasitology EIA Tests
Prevotella spp.
Pseudoflavonifractor spp.
Roseburia spp.
Ruminococcus spp.
Veillonella spp.
CPT Codes  
Specimen Requirements